

## Special Issue

# Pharmacotherapy of Neurodegeneration Disorders

### Message from the Guest Editors

A significant increase in the ageing of populations worldwide is especially prevalent in recent decades, with age-related rates steadily increasing. The progressive degeneration and/or death of neuronal cells, resulting in the manifestation of motor (ataxia) and mental disorders (dementia), is linked to a number of neurodegenerative diseases, characterized by the loss of neurons in certain areas of the brain. The current therapeutic strategies in neurodegenerative diseases are mainly aimed at influencing various symptoms, where increasing interest is paid to the key role of oxidative stress and inflammatory processes in the pathogenesis of neurodegenerative diseases. In this relationship, the isolation or synthesis of various biologically active molecules with potential anti-inflammatory and antioxidant effects would expand approaches for the therapy of these diseases beyond conventional treatment, which is accompanied by the manifestation of a number of adverse drug reactions. In addition, the search and the design of new chemically available multitarget agents will add to the search for contemporaneous strategies in neurodegenerative treatment.

### Guest Editors

Prof. Dr. Magdalena Kondeva-Burdina

Laboratory "Drug metabolism and drug toxicity", Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University-Sofia, Sofia, Bulgaria

Dr. Maya Georgieva

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University-Sofia, Sofia, Bulgaria

### Deadline for manuscript submissions

closed (28 February 2025)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/181110](https://mdpi.com/si/181110)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)